Abstract
Introduction
Warfarin and its companion anticoagulant drugs are the first line treatment to mitigate the risks related to atrial fibrillation, ventricular dysfunction, deep vein thrombosis and aortic valve replacement. However their therapeutic range is very narrow: therefore frequent sampling (at least once in 2-3 weeks) of the INR index (International Rationalized Ratio), i.e. the time required for the blood to clot, and careful dosage adjustments are needed for the INR to stay within its assigned range. The "trial &error" basis of the methods currently in use to fine tune the dosage for a given patient along with the response's variability due to genetic and behavioral factors can result in out of range periods and therefore in a non negligible risk of thromboembolic and bleeding events. Warfarin initiation is associated with one of the highest adverse events for any single drug due to high inter-individual variability. About 50% of patients fail to stabilize within the therapeutic range: for this reason most of these patients even with no contraindication to warfarin therapy are not receiving it because physicians are reluctant to initiate it in patient's elderly or with risk of bleeding. Genotyping of patients has been recently suggested in order to understand inter-individual variability and control its dose-INR relationship, particularly in the induction phase. This fact as been recognized by FDA whose labeling for Warfarin 2007 reads: "It cannot be emphasized too strongly that the treatment of each patient is a highly individualized matter". A notable contribution to patient genotyping is: [14] where it is shown that genetics variants of the enzyme that metabolized Warfarin cytochrome P450 CYP2C9 and VKORC1 contribute to differences in patients' response. Basically the same results have been obtained in a wide range of genetics investigations. More recently [3] [12] [15] variance of a new gene CYP4F2 have been shown to alter warfarin requirements.
While there is a relative large agreement of the value of genotypes for the induction phase, the debate is still open on its effectiveness in the long term therapeutic management [7] . Indeed in [1] it is shown that pharmacogenomics guided dosing failed to achieve a reduction of the patient average percentage INR outside the therapeutic range. This paper has two objectives: 1. Use data mining techniques in order to characterize patients according to their warfarin metabolism and hence their sensitivity to different doses. 2. Develop a Markov model to capture the dynamics of the patients response over the years Section 2 explains in detail the data sources and its preparation. The data mining algorithms are considered in Sect. 3 along with their results. Sect.4 is devoted to the Markov model, while sect.5 presents a comprehensive assessment of the results along with further research direction.
Data sources
We tested our approach on a sample of 1013 elderly (65+) patients. We imported data collected from the computerized databases in a database with three entities: patients, treatments and visits. The sample shows a prevalence of atrial fibrillation (76.11%). The genotyped sub-sample mirrors in a balanced way the relative weight of the features in the large one. In our study we extract from the 138 patients, only those with atrial fibrillation and so we work on a dataset of 135 patients. The allelic variant frequencies for the subset of 135 patients are summarized in 
The data mining algorithms
In this work, we introduce a particular index, called drug sensitivity (D sens ) to capture the dose-INR relationship which better characterizes the patient behavior. This index is represented by the ratio between dose and INR's variations, as follows: 
Clustering
In particular, since data are both categorical and numerical, we use a modified k-prototypes algorithm, proposed by Bushel et al. [2] , following an earlier paper of Huang [9] , for handling mixed data. In Fig. 2 is represented the components of the modified kprototypes algorithm for our mixed numeric and categorical dataset. The approach follows the k-means paradigm with randomization of initialization of the algorithm. The strategy involves constructing an objective function from the sum of the squared Euclidean distances for numeric data with simple matching for categorical values in order to measure dissimilarity of the samples. Furthermore, separate weighting terms are used to control the influence of each data domain on the clustering of the patients. A cluster's prototype is formed from the mean of the values for numeric features and the mode of the categorical values of all the samples in the group. Finally, the dynamic validity index (DVI) for numeric data was modified with a category utility (CU) measure, obtaining a DVI_CU index. With this index we can determine the optimal number of clusters in the mixed type data, like in Bushel et al. [2] . The DVI_CU index is computed as:
The DVI index, proposed by Shen et al. [13] , is based on an intra/inter ratio validity index that also includes scaling of the intra-and the inter-cluster distances. Furthermore, CU measure [8] defines the probability of matching a categorical feature value given a cluster versus the probability of the categorical feature value given the entire data set.
Fig. 2: schema of the implemented algorithm
In particular, DVI_CU is minimized over all k sets for each run of the modk-prototypes clustering algorithm. In our work, both the complete dataset and the genetic dataset are clustered using the modified k-prototypes clustering algorithm at values of k increasing from 2 to N, number of clusters. Values of DVI_CU index obtained for each value of k are reported in Fig. 3 and in Fig. 4 . We have the minimum value of this index, for complete dataset, with k=3 and DVI_CU equals to 1.11, as represented in Fig. 3. Fig. 4 shown the results obtained on the dataset composed by patients with genetic data. In this case, minimum DVI_CU index is obtained with k=3 and DVI_CU equals to 1.08. Results of clustering algorithms confirm the division of patients into three different classes, as proposed in the last subsection. To characterize better the behavior of a patient we compute INR average and variance of a time course of 6 INR measurements and include both these data in the feature set. So, we built new classification models with this new feature set and the obtained results, reported in Tab. 4 , are better both in term of CCI and F-measure. figure Fig. 6 , is possible to see that the hemorrhagic or thrombotic risk of a patient in negative D sens class is higher then that of a positive D sens patient. 
Drug sensitivity based classification

The Markov model
A Markov Chain (MC) is a discrete time stochastic process {X k }, with a finite number of states and transition probability matrix. The simplest possible model of our problem considers: three states (HIGH (over range), IN (in range), LOW (under range)); three dosing actions (dose decrease, increase and constant) and a different transition probability matrix for each drug sensitivity class. Assessment of results is in Fig. 8 , Fig. 9 and Fig. 10 . 
Assessments of results and future directions
In this paper authors use different classification methods to characterize patients according to their warfarin metabolism and hence their sensitivity to different doses. Finally, through a Markov model they try to capture the dynamics of the patient's response over the years. These promising results should be prospectively validated.
Since all clinical studies so far failed to demonstrate a beneficial impact of pharmacogenetic guided warfarin dosing and to achieve the primary end point reduction of out of range INR [7] , we feel that an accurate patient characterization and subset analysis is required to capture how the dynamics of INR is impacted by the genomic patients' features. The authors believe that a reduction in out of range time can be obtained through dosing approaches that capture this dynamic.
